Updated May 5, 2017

Rutgers University–New Brunswick is no longer considered an outbreak setting for meningitis B. We would like to thank our students for taking the health warnings seriously and taking the time to receive the vaccination series. Please continue the practice of good hygiene to help reduce the spread of disease.

If you have started the vaccine series, you should continue to receive all the recommended doses.

The risk of meningitis B at Rutgers University–New Brunswick is now considered the same as at any other university. The risk level is reduced due to the passage of time since the last case. Two students at Rutgers University–New Brunswick were diagnosed with identical strains of serogroup B meningococcal disease in March and April of 2016 prompting public health and University officials to recommend vaccination against serogroup B meningococcal disease for all undergraduates. If you have started the vaccine series, you should continue to receive all the recommended doses.

For the upcoming academic year, the New Jersey Department of Health recommends that all incoming students discuss receiving the meningitis B vaccine with their healthcare provider prior to arrival on campus. There are two vaccines against serogroup B meningococcal disease, Bexsero and Trumenba. Meningitis B is not included in the typical meningitis vaccine that is required for teenagers in the U.S. and specifically required by the state for college enrollment in New Jersey.